TABLE 1.
Baseline characteristics
| Study cohort (n = 61) | |
|---|---|
| Age | 66 (59–71) |
| Sex, n (%) | |
| Female | 5 (8.2) |
| Male | 56 (91.8) |
| Cirrhosis present | 44 (72.1) |
| Risk factorb | |
| HBV | 15 (24.6) |
| HCV | 21 (34.4) |
| Alcohol | 14 (23.0) |
| NASH | 4 (6.6) |
| Othera | 12 (19.7) |
| AFP ng/mL | 137 (7–1976) |
| AFP ≥ 400 ng/ml | 23 (39.0) |
| Child-Pugh Score, n (%) | |
| A5 | 26 (42.6) |
| A6 | 20 (32.8) |
| B7 | 9 (14.8) |
| B8 | 4 (6.6) |
| B9 | 1 (1.6) |
| C11 | 1 (1.6) |
| ALBI grade, n (%) | |
| 1 | 23 (37.7) |
| 2 | 34 (55.7) |
| 3 | 4 (6.6) |
| ECOG PS, n (%) | |
| 0 | 31 (50.8) |
| 1 | 29 (47.5) |
| 2 | 1 (1.6) |
| BCLC stage, n (%) | |
| A | 1 (1.6) |
| B | 17 (27.9) |
| C | 43 (70.5) |
| Extrahepatic spread | 27 (44.3) |
| Previous nonsystemic treatmentsc, n (%) | |
| Surgery | 23 (37.7) |
| Ablation | 10 (16.4) |
| TACE | 23 (37.7) |
| TARE | 11 (18.0) |
| EBRT | 7 (11.5) |
| No.of previous systemic treatments, n (%) | |
| 1 | 39 (63.9) |
| 2 | 11 (18.0) |
| 3 | 4 (6.6) |
| 4 | 2 (3.3) |
| 5 | 3 (4.9) |
| 6 | 1 (1.6) |
| 7 | 1 (1.6) |
| Median line of systemic treatment | 2 (2–3) |
| Any previous TKI | 46 (75.4) |
| Any previous IO | 29 (47.5) |
Displayed are medians (IQR) for continuous and frequencies and percentages for categorical variables.
Includes 2 patients with cryptogenic liver disease, 1 patient with Wilson’s disease, 1 patient with alpha-1-antitrypsin-associated liver disease, 1 patient with a history of liver adenoma that progressed to HCC and 6 patients with unknown etiology of liver disease/no underlying liver disease.
Patients can have multiple risk factors, i.e. numbers exceed 100%.
Patients can have multiple previous treatments.
Abbreviations: ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; EBRT, external beam radiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immune-oncological therapy; TARE/TACE, transarterial radio/chemoembolisation; TKI, tyrosine kinase inhibitors.